1. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Sharma, Manish; Dumbrava, Ecaterina Ileana; Carvajal, Richard; Catenacci, Daniel; Emens, Leisha; Hanna, Glenn; Juric, Dejan; Kang, Yoon-Koo; Lee, Jeeyun; Lee, Keun-Wook; Li, Bob; Moore, Kathleen; Pegram, Mark; Pohlmann, Paula; Rasco, Drew; Spira, Alexander; Tan, Antoinette; Wang, Ding; Ackerman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Sharma, Manish; Dumbrava, Ecaterina Ileana; Carvajal, Richard; Catenacci, Daniel; Emens, Leisha; Hanna, Glenn; Juric, Dejan; Kang, Yoon-Koo; Lee, Jeeyun; Lee, Keun-Wook; Li, Bob; Moore, Kathleen; Pegram, Mark; Pohlmann, Paula; Rasco, Drew; Spira, Alexander; Tan, Antoinette; Wang, Ding; Ackerman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models. (9th November 2020) Authors: LeBlanc, Heidi; Pearson, Cecelia; Kenkel, Justin; Blum, LIsa; Ho, Po; Luo, Angela; Laura, Richard; Zhou, Matthew; Gregorio, Joshua; Luo, Andrew; Ackerman, Shelley; Safina, Brian; Dornan, David; Alonso, Michael; Kowanetz, Marcin Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models. (9th November 2020) Authors: LeBlanc, Heidi; Pearson, Cecelia; Kenkel, Justin; Blum, LIsa; Ho, Po; Luo, Angela; Laura, Richard; Zhou, Matthew; Gregorio, Joshua; Luo, Andrew; Ackerman, Shelley; Safina, Brian; Dornan, David; Alonso, Michael; Kowanetz, Marcin Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer. (6th November 2014) Authors: Ziai, James; Huseni, Mahrukh; Foreman, Oded; Eastham-Anderson, Jeffrey; Xiao, Yuanyuan; Chu, Felix; Kowanetz, Marcin; Hegde, Priti S; Kim, Jeong Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Issue 7 (July 2019) Authors: West, Howard; McCleod, Michael; Hussein, Maen; Morabito, Alessandro; Rittmeyer, Achim; Conter, Henry J; Kopp, Hans-Georg; Daniel, Davey; McCune, Steven; Mekhail, Tarek; Zer, Alona; Reinmuth, Niels; Sadiq, Ahad; Sandler, Alan; Lin, Wei; Ochi Lohmann, Tania; Archer, Venice; Wang, Lijia; Kowanetz, M... Journal: Lancet oncology Issue: Volume 20:Issue 7(2019) Page Start: 924 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Issue 5 (May 2019) Authors: Reck, Martin; Mok, Tony S K; Nishio, Makoto; Jotte, Robert M; Cappuzzo, Federico; Orlandi, Francisco; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodríguez-Abreu, Delvys; Moro-Sibilot, Denis; Thomas, Christian A; Barlesi, Fabrice; Finley, Gene; Lee, Anthony; Coleman, Shelley; Deng, Yu; Kowanetz, Marc... Journal: Lancet Issue: Volume 7:Issue 5(2019) Page Start: 387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Issue 10030 (30th April 2016) Authors: Fehrenbacher, Louis; Spira, Alexander; Ballinger, Marcus; Kowanetz, Marcin; Vansteenkiste, Johan; Mazieres, Julien; Park, Keunchil; Smith, David; Artal-Cortes, Angel; Lewanski, Conrad; Braiteh, Fadi; Waterkamp, Daniel; He, Pei; Zou, Wei; Chen, Daniel S; Yi, Jing; Sandler, Alan; Rittmeyer, Achim Journal: Lancet Issue: Volume 387:Issue 10030(2016) Page Start: 1837 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Issue 10066 (21st January 2017) Authors: Rittmeyer, Achim; Barlesi, Fabrice; Waterkamp, Daniel; Park, Keunchil; Ciardiello, Fortunato; von Pawel, Joachim; Gadgeel, Shirish M; Hida, Toyoaki; Kowalski, Dariusz M; Dols, Manuel Cobo; Cortinovis, Diego L; Leach, Joseph; Polikoff, Jonathan; Barrios, Carlos; Kabbinavar, Fairooz; Frontera, Osva... Journal: Lancet Issue: Volume 389:Issue 10066(2017) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. (April 2017) Authors: Chan, Oscar Siu Hong; Kowanetz, Marcin; Ng, Wai Tong; Koeppen, Hartmut; Chan, Lai Kwan; Yeung, Rebecca Mei Wan; Wu, Haiyan; Amler, Lukas; Mancao, Christoph Journal: Oral oncology Issue: Volume 67(2017) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗